Diabetes mellitus is a chronic metabolic disease that has increased blood glucose level as a defining feature which eventually causes multiple complications including gastrointestinal problems. Type 2 diabetes mellitus (T2DM) represents a risk factor for stomach inflammation and gastrointestinal problems including ulcer diseases. Gastrointestinal symptoms include functional dyspepsia, abdominal pain, diarrhea and gastric ulcers that could be severe and progressed to bleeding and perforation. Gastric ulcer in T2DM has many causes but the most important of them is higher possibility of Helicobacter pylori infection. However, the current mini-review correlates T2DM and gastric ulcer as one of its complications in susceptible individuals. Yet, specific treatments for gastric ulcer are histamine-H2 blockers, proton pump inhibitors, antacids and antibiotics that aimed to reduce discomfort, treat the ulcer, and prevent a recurrence. In addition, many experimental studies provided a protective role for many anti-diabetic drugs in gastric ulcer during T2DM such as metformin, pioglitazone and glucagon-like peptide-1analogues. Many of these anti-diabetic drugs may promote tissue generation and the healing of ulcerative wounds by producing anti-inflammatory and anti-oxidative effects in the tissue around the ulcer of diabetic rats. The presence of sufficient clinical studies concerning this effect and the development of novel strategies are warranted in the near future.